Metastatic Renal Cell Carcinoma Therapeutics
1. Nexavar patent expiration
Treatment: Treatment of carcinoma of the thyroid; Treatment of advanced renal cell carcinoma; Treatment of unresectable hepatocellular carcinoma; Treatment of unresectable hepatocellular carcinoma, advanced rena...
NEXAVAR's oppositions filed in EPO
NEXAVAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8124630 | BAYER HLTHCARE | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US8618141 | BAYER HLTHCARE | Aryl ureas with angiogenesis inhibiting activity |
Feb, 2023
(2 years ago) | |
| US8841330 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US7897623 | BAYER HLTHCARE | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US7235576 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US9737488 | BAYER HLTHCARE | Pharmaceutical composition for the treatment of cancer |
Sep, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 20, 2012 |
| New Indication(I-677) | Nov 22, 2016 |
| Orphan Drug Exclusivity(ODE-56) | Nov 22, 2020 |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Dosage: TABLET
How can I launch a generic of NEXAVAR before it's drug patent expiration?
More Information on Dosage
NEXAVAR family patents
2. Sutent patent expiration
Treatment: Treatment of protein kinase related disorders, such as gastrointestinal stromal tumors, renal cell carcinoma and advanced pancreatic neuroendocrine tumors, with sunitinib; Treatment of gastrointestina...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7125905 (Pediatric) | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug, 2021
(4 years ago) | |
|
US6573293 (Pediatric) | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug, 2021
(4 years ago) | |
|
US7211600 (Pediatric) | CPPI CV | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Jun, 2021
(4 years ago) | |
| US6573293 | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb, 2021
(4 years ago) | |
| US7211600 | CPPI CV | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Dec, 2020
(5 years ago) | |
| US7125905 | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-639) | May 20, 2014 |
| New Indication(I-755) | Nov 16, 2020 |
| Pediatric Exclusivity(PED) | May 16, 2021 |
Drugs and Companies using SUNITINIB MALATE ingredient
Market Authorisation Date: 26 January, 2006
Dosage: CAPSULE
How can I launch a generic of SUTENT before it's drug patent expiration?
More Information on Dosage
SUTENT family patents
3. Votrient patent
expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114885 | NOVARTIS | Chemical compounds |
Dec, 2021
(4 years ago) | |
| US7262203 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Dec, 2021
(4 years ago) | |
| US7105530 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Oct, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2014 |
| New Indication(I-649) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-23) | Apr 26, 2019 |
Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient
NCE-1 date: 19 October, 2013
Market Authorisation Date: 19 October, 2009
Dosage: TABLET
More Information on Dosage
VOTRIENT family patents